CeriBell (NASDAQ:CBLL) Price Target Raised to $31.00

CeriBell (NASDAQ:CBLL) had its price objective raised by Canaccord Genuity Group from $30.00 to $31.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

CBLL has been the subject of several other research reports. William Blair assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set an “outperform” rating for the company. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective for the company. TD Cowen assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $31.00 target price on the stock. Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $31.20.

CeriBell Trading Down 3.7 %

Shares of CeriBell stock opened at $26.53 on Wednesday. CeriBell has a 1 year low of $23.00 and a 1 year high of $29.53.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The company had revenue of $17.20 million during the quarter, compared to analysts’ expectations of $17.06 million. Sell-side analysts forecast that CeriBell will post -1.55 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.